A Pragmatic Cluster-Randomized Trial of a Standing Order Entry Intervention for Colony-Stimulating Factor Use Among Patients at Intermediate Risk for Febrile Neutropenia.
Dawn L HershmanAasthaa BansalSean D SullivanWilliam E BarlowKathryn B ArnoldKate WatabayashiAri Bell-BrownNguyet A Le-LindqwisterCarrie L DulUrsa A Brown-GlabermanRobert J BehrensVictor VogelNitya AlluriScott D RamseyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Although implementation of a SOE intervention for PP-CSF significantly increased PP-CSF use among patients receiving first-line intermediate-risk regimens, FN rates were low and did not differ between arms. Although this guideline-informed SOE influenced prescribing, the results suggest that neither SOE nor PP-CSF provides sufficient benefit to justify their use for all patients receiving first-line intermediate-risk regimens.